Nifty
:
25405.30
Sensex
:
83239.47
-48.10 (-0.19%)
-170.22 (-0.20%)
Nifty
Sensex
:
:
25405.30
83239.47
-48.10 (-0.19%)
-170.22 (-0.20%)

Aurobindo Pharma Ltd.

Pharmaceuticals & Drugs - Global

Rating :
63/99

BSE: 524804 | NSE: AUROPHARMA

NSE BSE
1156.10
03-Jul-2025
  • Open
  • High
  • Low
  • Previous Close
  •  1164
  •  1164
  •  1144.2
  •  1158.00
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1234364
  •  1423239163
  •  1592
  •  1010

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 67,114.53
  • 19.25
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 66,820.72
  • N/A
  • 2.06

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 51.82%
  • 0.44%
  • 5.47%
  • FII
  • DII
  • Others
  • 15.33%
  • 23.65%
  • 3.29%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.12
  • 4.66
  • 7.33

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.59
  • 3.73
  • 5.91

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.25
  • 2.10
  • 6.21

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.19
  • 16.73
  • 20.37

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.39
  • 2.04
  • 1.90

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 9.82
  • 9.41
  • 9.80

Earnings Forecasts:

(Updated: 06-06-2025)
Description
2024
2025
2026
2027
Adj EPS
54.16
60.02
71.84
79.02
P/E Ratio
21.35
19.26
16.09
14.63
Revenue
28705
31378
34307
36970
EBITDA
5843
6605
7302
7816
Net Income
3173
3486
4137
4645
ROA
7.5
7.4
8.7
9
P/B Ratio
3.43
2.06
1.86
1.67
ROE
11.2
11.16
11.93
12.35
FCFF
-316
1884
3581
3657
FCFF Yield
-0.47
2.82
5.37
5.48
Net Debt
319
27
-1665
-2748
BVPS
336.6
562.21
623
693.02

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Net Sales
8,382.12
7,580.15
10.58%
7,978.52
7,351.78
8.53%
7,796.07
7,219.42
7.99%
7,567.02
6,850.52
10.46%
Expenses
6,590.20
5,907.34
11.56%
6,400.54
5,750.47
11.30%
6,229.93
5,845.98
6.57%
5,947.45
5,699.15
4.36%
EBITDA
1,791.92
1,672.81
7.12%
1,577.98
1,601.31
-1.46%
1,566.14
1,373.44
14.03%
1,619.57
1,151.37
40.66%
EBIDTM
21.38%
22.07%
19.78%
21.78%
20.09%
19.02%
21.40%
16.81%
Other Income
134.81
135.62
-0.60%
157.29
162.52
-3.22%
136.00
186.98
-27.26%
220.93
116.33
89.92%
Interest
115.02
89.43
28.61%
118.48
75.55
56.82%
112.70
68.18
65.30%
111.04
56.55
96.36%
Depreciation
444.43
354.33
25.43%
418.53
423.27
-1.12%
382.28
417.50
-8.44%
404.18
326.56
23.77%
PBT
1,367.28
1,242.56
10.04%
1,198.26
1,265.01
-5.28%
1,207.16
1,074.74
12.32%
1,325.28
814.84
62.64%
Tax
432.26
322.55
34.01%
354.28
322.45
9.87%
390.51
323.70
20.64%
405.67
242.32
67.41%
PAT
935.02
920.01
1.63%
843.98
942.56
-10.46%
816.65
751.04
8.74%
919.61
572.52
60.62%
PATM
11.15%
12.14%
10.58%
12.82%
10.48%
10.40%
12.15%
8.36%
EPS
15.56
15.51
0.32%
14.56
15.98
-8.89%
14.07
12.92
8.90%
15.69
9.74
61.09%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Net Sales
31,723.73
29,001.87
24,855.38
23,455.49
24,774.62
23,098.51
19,563.55
16,463.03
14,909.54
13,794.65
12,120.52
Net Sales Growth
9.39%
16.68%
5.97%
-5.32%
7.26%
18.07%
18.83%
10.42%
8.08%
13.81%
 
Cost Of Goods Sold
13,026.24
11,348.78
10,190.48
9,238.91
8,827.71
8,720.74
7,886.32
6,085.55
5,911.00
5,612.30
5,099.89
Gross Profit
18,697.49
17,653.09
14,664.90
14,216.58
15,946.91
14,377.77
11,677.23
10,377.48
8,998.54
8,182.35
7,020.63
GP Margin
58.94%
60.87%
59.00%
60.61%
64.37%
62.25%
59.69%
63.04%
60.35%
59.32%
57.92%
Total Expenditure
25,168.12
23,158.87
21,136.74
19,070.95
19,441.22
18,234.20
15,611.61
12,691.28
11,475.26
10,606.53
9,556.90
Power & Fuel Cost
-
826.03
842.63
626.86
589.28
587.68
556.79
470.95
437.14
419.26
359.60
% Of Sales
-
2.85%
3.39%
2.67%
2.38%
2.54%
2.85%
2.86%
2.93%
3.04%
2.97%
Employee Cost
-
3,922.94
3,522.25
3,450.92
3,535.02
3,219.18
2,584.87
2,130.84
1,767.76
1,542.62
1,302.26
% Of Sales
-
13.53%
14.17%
14.71%
14.27%
13.94%
13.21%
12.94%
11.86%
11.18%
10.74%
Manufacturing Exp.
-
3,191.71
2,810.03
2,502.98
2,875.39
2,331.41
2,037.95
1,611.12
1,309.64
1,256.18
1,022.70
% Of Sales
-
11.01%
11.31%
10.67%
11.61%
10.09%
10.42%
9.79%
8.78%
9.11%
8.44%
General & Admin Exp.
-
1,534.59
1,386.66
1,335.03
1,473.59
1,320.69
1,006.68
1,068.22
997.32
686.38
666.38
% Of Sales
-
5.29%
5.58%
5.69%
5.95%
5.72%
5.15%
6.49%
6.69%
4.98%
5.50%
Selling & Distn. Exp.
-
1,684.72
1,685.76
1,496.67
1,564.17
1,524.75
1,125.76
1,025.85
848.43
877.14
878.98
% Of Sales
-
5.81%
6.78%
6.38%
6.31%
6.60%
5.75%
6.23%
5.69%
6.36%
7.25%
Miscellaneous Exp.
-
650.10
698.93
419.58
576.06
529.75
413.24
298.75
203.97
212.65
878.98
% Of Sales
-
2.24%
2.81%
1.79%
2.33%
2.29%
2.11%
1.81%
1.37%
1.54%
1.87%
EBITDA
6,555.61
5,843.00
3,718.64
4,384.54
5,333.40
4,864.31
3,951.94
3,771.75
3,434.28
3,188.12
2,563.62
EBITDA Margin
20.66%
20.15%
14.96%
18.69%
21.53%
21.06%
20.20%
22.91%
23.03%
23.11%
21.15%
Other Income
649.03
557.38
290.59
322.58
380.85
191.87
155.32
101.98
115.89
203.80
96.71
Interest
457.24
289.71
140.48
48.64
74.49
305.13
262.60
77.72
66.72
256.70
159.87
Depreciation
1,649.42
1,521.66
1,244.58
1,126.52
1,055.39
966.71
667.95
557.97
427.63
392.37
332.61
PBT
5,097.98
4,589.01
2,624.17
3,531.96
4,584.37
3,784.34
3,176.71
3,238.04
3,055.82
2,742.85
2,167.85
Tax
1,582.72
1,211.02
684.85
725.63
2,009.77
899.35
726.85
818.27
759.65
720.71
596.59
Tax Rate
31.05%
27.54%
26.10%
21.32%
27.16%
23.93%
23.53%
25.27%
24.86%
26.28%
27.52%
PAT
3,515.26
3,172.97
1,927.50
2,648.15
5,390.20
2,860.31
2,362.03
2,420.03
2,296.64
2,023.64
1,575.77
PAT before Minority Interest
3,517.57
3,168.97
1,927.65
2,647.11
5,389.18
2,858.86
2,361.80
2,419.77
2,296.17
2,022.14
1,571.26
Minority Interest
2.31
4.00
-0.15
1.04
1.02
1.45
0.23
0.26
0.47
1.50
4.51
PAT Margin
11.08%
10.94%
7.75%
11.29%
21.76%
12.38%
12.07%
14.70%
15.40%
14.67%
13.00%
PAT Growth
10.33%
64.62%
-27.21%
-50.87%
88.45%
21.10%
-2.40%
5.37%
13.49%
28.42%
 
EPS
60.52
54.63
33.19
45.59
92.81
49.25
40.67
41.67
39.54
34.84
27.13

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Shareholder's Funds
29,842.80
26,839.85
24,575.98
21,929.87
16,824.67
13,890.78
11,680.42
9,371.91
7,287.30
5,155.91
Share Capital
58.59
58.59
58.59
58.59
58.59
58.59
58.59
58.59
58.52
29.20
Total Reserves
29,784.21
26,781.26
24,517.39
21,871.28
16,766.08
13,832.13
11,621.76
9,313.22
7,227.50
5,126.71
Non-Current Liabilities
1,808.94
866.87
903.10
807.27
555.09
358.13
594.11
102.07
583.85
1,591.60
Secured Loans
2,134.90
618.96
249.21
168.49
0.00
48.88
451.20
177.59
380.10
773.54
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
131.07
0.00
3.81
362.71
587.93
Long Term Provisions
225.70
172.72
171.79
157.11
74.71
46.54
55.86
39.13
23.36
24.35
Current Liabilities
12,199.13
11,493.78
8,155.98
10,665.05
11,384.64
12,020.57
8,665.89
6,605.60
7,840.22
6,136.40
Trade Payables
4,454.16
3,871.31
2,703.05
2,794.68
2,576.06
2,552.18
2,372.90
2,154.70
2,457.03
2,051.13
Other Current Liabilities
3,070.63
2,979.91
3,106.51
2,684.31
2,874.56
2,510.51
1,967.42
1,286.82
1,577.58
1,364.95
Short Term Borrowings
4,168.54
4,230.43
2,117.83
4,803.78
5,422.30
6,573.21
4,031.34
2,902.72
3,672.68
2,502.08
Short Term Provisions
505.80
412.13
228.59
382.28
511.72
384.67
294.23
261.36
132.93
218.24
Total Liabilities
43,858.87
39,212.50
33,633.13
33,401.31
28,764.54
26,271.07
20,942.24
16,081.66
15,713.92
12,909.73
Net Block
14,492.79
11,023.69
10,532.09
9,373.58
9,396.47
8,474.85
6,520.68
4,833.78
4,179.69
3,705.64
Gross Block
23,447.77
18,593.32
15,943.09
13,613.33
12,441.26
10,497.62
7,894.78
5,635.49
4,569.83
5,446.13
Accumulated Depreciation
8,952.24
7,569.63
5,411.00
4,239.75
3,044.79
2,022.77
1,374.10
801.71
390.14
1,740.49
Non Current Assets
19,653.24
17,666.83
15,510.44
13,577.80
12,352.03
10,938.77
8,764.08
6,875.48
5,419.57
4,610.93
Capital Work in Progress
3,868.72
5,390.01
3,747.20
3,061.53
1,985.92
1,668.46
1,583.04
1,458.08
848.14
370.35
Non Current Investment
321.65
391.74
618.30
431.22
554.69
360.20
311.52
245.85
122.94
0.14
Long Term Loans & Adv.
714.55
794.00
575.33
658.44
378.34
396.64
261.91
256.48
236.56
455.27
Other Non Current Assets
255.53
67.39
37.52
53.03
36.61
38.62
86.93
81.29
32.24
30.25
Current Assets
23,771.92
21,459.91
18,043.59
19,823.51
16,412.51
15,332.30
12,178.16
9,206.18
10,294.35
8,298.80
Current Investments
50.58
151.00
378.85
159.79
0.02
0.02
0.02
0.02
0.02
19.65
Inventories
9,808.23
8,511.23
7,553.85
9,026.57
7,699.87
7,245.60
5,858.41
4,330.54
4,056.14
3,611.30
Sundry Debtors
4,816.74
4,466.38
4,012.26
3,503.28
4,315.16
3,413.78
3,080.20
2,765.33
4,606.68
3,539.17
Cash & Bank
6,278.30
6,084.20
4,190.01
5,474.28
2,842.15
1,957.18
1,262.25
513.48
800.26
469.11
Other Current Assets
2,818.07
554.71
393.95
601.29
1,555.31
2,715.72
1,977.28
1,596.81
831.25
659.57
Short Term Loans & Adv.
2,298.62
1,692.39
1,514.67
1,058.30
1,065.96
795.90
753.96
512.09
366.88
387.90
Net Current Assets
11,572.79
9,966.13
9,887.61
9,158.46
5,027.87
3,311.73
3,512.27
2,600.58
2,454.13
2,162.40
Total Assets
43,425.16
39,126.74
33,554.03
33,401.31
28,764.54
26,271.07
20,942.24
16,081.66
15,713.92
12,909.73

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Cash From Operating Activity
2,434.52
2,386.75
5,016.48
3,329.05
4,381.28
1,650.97
1,954.52
3,278.58
1,419.76
1,236.81
PBT
4,379.99
2,612.50
3,372.74
7,343.59
3,743.04
3,091.35
3,241.18
3,060.84
2,744.30
2,167.85
Adjustment
1,496.24
1,586.47
1,344.13
-1,662.64
1,091.17
813.95
535.02
408.92
487.50
406.28
Changes in Working Capital
-1,675.07
-1,094.98
1,557.80
-1,066.65
307.91
-1,484.50
-1,123.12
582.52
-1,079.41
-841.73
Cash after chg. in Working capital
4,201.16
3,103.99
6,274.67
4,614.30
5,142.12
2,420.80
2,653.08
4,052.28
2,152.39
1,732.40
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,766.64
-717.24
-1,258.19
-1,285.25
-760.84
-769.83
-698.56
-773.70
-732.63
-495.59
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-4,255.95
-3,977.75
-3,211.56
598.69
-1,567.64
-2,902.59
-1,926.59
-1,787.04
-1,445.21
-1,397.97
Net Fixed Assets
2,277.63
-503.75
1,473.74
-428.03
-760.60
-799.00
-771.00
-1,092.24
125.11
-533.87
Net Investments
-5,288.07
-1,521.01
-1,574.43
-2,482.52
-188.35
-371.56
-285.55
-498.60
-170.60
-140.13
Others
-1,245.51
-1,952.99
-3,110.87
3,509.24
-618.69
-1,732.03
-870.04
-196.20
-1,399.72
-723.97
Cash from Financing Activity
800.42
1,814.41
-2,969.27
-1,364.94
-1,947.18
1,919.06
864.15
-1,915.26
365.44
93.21
Net Cash Inflow / Outflow
-1,021.01
223.41
-1,164.35
2,562.80
866.46
667.44
892.08
-423.72
339.99
-67.95
Opening Cash & Equivalents
4,392.27
4,162.51
5,329.91
2,746.82
1,875.58
1,209.94
318.03
743.49
403.81
148.02
Closing Cash & Equivalent
3,385.43
4,392.27
4,162.51
5,329.91
2,746.82
1,875.58
1,209.94
319.63
743.50
461.10

Financial Ratios

Consolidated /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Book Value (Rs.)
509.35
458.10
419.46
374.29
287.16
237.08
199.36
159.96
124.50
88.29
ROA
7.63%
5.29%
7.90%
17.34%
10.39%
10.00%
13.07%
14.44%
14.13%
14.03%
ROE
11.18%
7.50%
11.38%
27.81%
18.62%
18.47%
22.99%
27.57%
32.51%
35.29%
ROCE
13.76%
9.39%
12.71%
30.33%
18.79%
17.97%
22.72%
24.92%
27.35%
27.18%
Fixed Asset Turnover
2.84
2.95
3.24
3.73
4.12
4.36
2.44
2.96
2.79
2.55
Receivable days
28.34
30.42
28.69
29.37
29.85
29.56
64.66
89.16
106.53
91.84
Inventory Days
55.92
57.65
63.29
62.82
57.72
59.64
112.70
101.43
100.27
88.91
Payable days
133.88
117.74
108.60
111.03
53.30
58.56
67.77
75.73
81.70
67.49
Cash Conversion Cycle
-49.62
-29.67
-16.62
-18.84
34.27
30.63
109.58
114.86
125.10
113.25
Total Debt/Equity
0.21
0.18
0.10
0.23
0.33
0.50
0.41
0.36
0.69
0.86
Interest Cover
16.12
19.60
70.34
100.33
13.32
12.76
42.66
46.80
11.69
14.56

Annual Reports:

FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015

News Update:


  • Aurobindo Pharma’s arm obtains marketing authorization for Dazublys
    3rd Jul 2025, 10:20 AM

    The company’s arm has obtained marketing authorization from the European Commission

    Read More
  • Aurobindo Pharma’s arm restarts Penicillin-G manufacturing facility in AP
    30th Jun 2025, 14:59 PM

    Lyfius Pharma has re-started the production at its Penicillin-G manufacturing facility, after receiving the consent to operate from APPCB

    Read More
  • Aurobindo Pharma’s arm obtains marketing authorization from MHRA for Dyrupeg
    25th Jun 2025, 10:10 AM

    Earlier in April 2025, Dyrupeg received marketing authorization in the European Union from the European Commission

    Read More
  • Aurobindo Pharma’s arm incorporates wholly owned subsidiary in USA
    16th Jun 2025, 09:29 AM

    The object of incorporation of this wholly owned subsidiary is to expand the Pharmaceutical Products business in USA

    Read More
  • Aurobindo Pharma’s arm incorporates wholly owned subsidiary in Netherlands
    28th May 2025, 18:02 PM

    The object of incorporation of this WOS is to expand the biopharma products business in Europe

    Read More
  • Aurobindo Pharma’s arm obtains marketing authorisation from MHRA for biosimilar Zefylti
    14th May 2025, 09:24 AM

    Earlier in February 2025, Zefylti has received the marketing authorisation in the European Union from the European Commission

    Read More
  • Aurobindo Pharma’s arm gets USFDA's nod to manufacture, market Dasatinib tablets
    23rd Apr 2025, 14:41 PM

    The product is expected to be launched in Q1FY26

    Read More
  • Aurobindo Pharma gets USFDA’s nod to manufacture, market Rivaroxaban Tablets USP
    14th Apr 2025, 09:44 AM

    The product will be launched in Q1FY26

    Read More
  • USFDA concludes inspection at Raleigh plant of Aurobindo Pharma’s arm
    12th Apr 2025, 12:18 PM

    At the conclusion, the USFDA issued a Form 483 with 11 observations

    Read More
  • Aurobindo Pharma’s arm gets marketing authorization for Dyrupeg
    7th Apr 2025, 11:30 AM

    Earlier in January 2025, the Committee for Medicinal Products of European Medicines Agency had adopted positive opinion recommending the approval of Dyrupeg

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.